DSP Healthcare Fund Regular-Growth
The fund is rated 4 stars. The strongest areas were investment selection within each asset type and investment selection within each industry, while balance between returns and downside risk provided some support. Higher annual fee of 2.05% and above-average fund size of Rs 3,835.28 crore were minor drawbacks.
This fund has a good track record with Asset Selection/Timing, a good track record with Stock Selection/Timing. It is important to note, however, that this fund has a 3835.275 AUM and a 2.05 expense ratio. Considering all these factors, we have rated this fund as 4.0 star.
எங்கள் score நீண்டகால performance, risk மற்றும் consistency-ஐ மதிப்பிடுகிறது — past returns மட்டும் அல்ல.
Returns
7 Oct 2026 நிலவரப்படி
Risk ratios
30 Sep 2026 நிலவரப்படி
Portfolio
31 Aug 2026 நிலவரப்படி
Market-cap பிரிவு
துறை ஒதுக்கீடு
Holdings (32)
| Holding | Fund-இன் % | மதிப்பு | பங்குகள் |
|---|---|---|---|
| Ipca Laboratories Ltd. | 8.74% | ₹335.02 Cr | 16,96,381 |
| Sun Pharmaceutical Industries Ltd. | 7.95% | ₹304.78 Cr | 15,35,592 |
| Sai Life Sciences Ltd. | 7.45% | ₹285.72 Cr | 19,57,356 |
| Cipla Ltd. | 7.35% | ₹282.03 Cr | 20,01,379 |
| Apollo Hospitals Enterprise Ltd. | 6.47% | ₹248.03 Cr | 2,78,729 |
| Gland Pharma Ltd. | 5.98% | ₹229.5 Cr | 7,95,267 |
| Globus Medical Inc | 5.44% | ₹208.77 Cr | 2,68,800 |
| Divi's Laboratories Ltd. | 4.15% | ₹159.26 Cr | 1,68,223 |
| Alkem Laboratories Ltd. | 4.08% | ₹156.61 Cr | 2,93,861 |
| Cohance Lifesciences Ltd. | 3.81% | ₹146.04 Cr | 32,02,999 |
Fund விவரங்கள்
Long term capital growth. Investment in equity and equity related Securities of healthcare and pharmaceutical companies/entities.
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies/entities.
Exit load of 0.50% if redeemed within 1 month.